IMFINZI (durvalumab) is indicated:
- For the treatment of patients with locally advanced, unresectable, Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following platinum-based chemoradiation therapy.1
- For the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with etoposide and either carboplatin or cisplatin.1
Product MonographSafety Information
Would you like to receive updated IMFINZI resources or
information on AstraZeneca Oncology products?
Nurse Kit Resources
imAR Handbook
High-level details concerning imAEs, how to recognize them, and how to manage them.
imAR Checklist
A concise checklist that allows you to run through potential imARs during your patient consultation.
Pocket Guide
A tool that you can carry with you at all times that provides an overview of imAEs and their management.
GP/Pharmacist ImAR Letter
To give to pharmacists and healthcare professionals in your centre/clinic so they can better understand the patient’s treatment and how to manage their potential side effects.
Patient Side Effects Tracker
Tear Pad
A tool for your patients to track and communicate their side effects in a clear and comprehensive table.
PACIFIC Trail Paper
Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;379(24):2342-2350.
Reprint of the pivotal PACIFIC trial overall survival results, as published in the New England Journal of Medicine.
PACIFIC Postcard
Overview of the IMFINZI indication and its use in the PACIFIC Regimen.
For Patients
IMFINZI Note Card
A small card for patients to take notes when discussing their IMFINZI treatment plan.
Chemoradiation Therapy Postcard
An overview of the definitive platinum-based concurrent chemoradiation therapy (cCRT) regimens received by patients prior to their enrollment in the PACIFIC Study.
Clinical Efficacy and Dosing Guide
A review of IMFINZI clinical efficacy results from the PACIFIC trial, and recommended dosing and administration with adjustment guidance.
PACIFIC Pivotal Paper
Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;379(24):2342-2350.
Reprint of the pivotal PACIFIC trial overall survival results, as published in the New England Journal of Medicine.
CASPIAN Pivotal Paper
Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929-1939.
Reprint of the pivotal CASPIAN trial overall survival results, as published in The Lancet.
Healthcare Professionals – Medical Information Inquiries
PHONE: 1-877-404-8277 (toll-free)
E-MAIL: ask-medical@astrazeneca.com
WEB: medicalinformation.astrazeneca.ca
Clinical Efficacy and Dosing Guide
A review of IMFINZI clinical efficacy results from the PACIFIC and CASPIAN trials, and recommended dosing and administration with adjustment guidance.
imAR Handbook
High-level details concerning imARs, how to recognize them, and how to manage them.
The AstraZeneca Oncology Patient Support Program
The AstraZeneca Oncology Patient Support Program is an initiative designed to provide educational and medication support for patients who have been prescribed IMFINZI. For program inquiries and more information, call 1-877-280-6208 (8 a.m. to 8 p.m. EST Monday to Friday).
Patient Support Program Patient Guide
Provides SCLC patients with key information about AstraZeneca Patient Support Program and necessary steps for enrolment.
Patient Information and Side Effects Brochure
Provides patients with key information about IMFINZI treatment and how to recognize possible side effects.
Available in 13 languages
Caregiver Brochure
Guidance for IMFINZI patients’ loved ones to help them through the treatment process.
Clinical use:
The safety and efficacy of IMFINZI in patients younger than 18 years of age have not been established.
No overall differences in safety or efficacy were reported between elderly patients (≥65 years of age) and younger patients (<65 years of age).
Contraindications:
- Hypersensitivity to IMFINZI or any ingredient in the formulation or component of the container.
Relevant warnings and precautions:
- Immune-mediated adverse reactions including:
- Pneumonitis
- Hepatitis
- Colitis
- Endocrinopathies (hypothyroidism, hyperthyroidism, thyroiditis, adrenal insufficiency, hypophysitis/hypopituitarism, type 1 diabetes mellitus)
- Nephritis
- Rash
- Other potential immune-mediated adverse reactions such as immune-related thrombocytopenia (of which one was fatal), myocarditis, pancreatitis, aseptic meningitis, uveitis, myositis, and polymyositis (fatal), myasthenia gravis (in clinical studies outside the pooled data set); Stevens Johnson Syndrome/toxic epidermal necrosis, rhabdomyolysis, encephalitis, demyelinating polyneuropathy, autoimmune hemolytic anemia, Guillain-Barré syndrome (reported with other PD-L1 blocking antibodies)
- Administer under the supervision of health care professionals experienced in the treatment of cancer
- Infections
- Infusion-related reactions
- Fertility
- Pregnant and nursing women
- Elderly
- Driving or operating machinery
For more information:
Please consult the IMFINZI Product Monograph at
https://www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/imfinzi-product-monograph-en.pdf for important information relating to adverse reactions, drug interactions and dosing, which has not been discussed in this piece.
The Product Monograph is also available by calling us at 1-800-668-6000.
Reference: 1. PrIMFINZI® Product Monograph. AstraZeneca Canada Inc. April 4, 2022.